DURASCREEN SUNBLOCK GETS NEW DERM SALES FORCE of 40 reps to back the Pierre Fabre OTC product's relaunch. The dermatological sales force will operate as a separate sales division within the French cosmetics and toiletries company, working strictly with dermatologists to market DuraScreen and Fabre's other "dermatologist-recommended" products, the company said. Pierre Fabre Dermo-Cosmetique acquired distribution rights to DuraScreen, which was developed by Penederm, from Schwarz Pharma in August.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The remarks from the new CBER director suggest Prasad will not be involved in most product-specific decisions.
A UK research team has used artificial intelligence to find new treatments for cancer using existing US Food and Drug Administration-approved medicines that are not normally not used for the disease.
The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.
